Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671593 · ClinicalTrials.gov registry record · Phase 1
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge
A Phase 1 study, sponsored by John Sundy.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00671593: Clinical Trial Phase 1 study, sponsored by John Sundy.
NCT00671593 is a Phase 1 study that was terminated before completion, run by John Sundy. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671593, a Phase 1 study, was terminated before completion, sponsored by John Sundy.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study) for drug targets.
Interventions
- BIOLOGICAL Diluent
- BIOLOGICAL House Dust Mite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671593
The ClinicalTrials.gov registry entry for NCT00671593 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Sundy, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diluent is the first listed.
NCT00671593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671593 about?
NCT00671593 is a clinical study titled "Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge". The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. This approach is designed to identify novel genes associated wi...
What is the current status of trial NCT00671593?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00671593?
The interventions under investigation include: Diluent (BIOLOGICAL), House Dust Mite (BIOLOGICAL).
Who is sponsoring clinical trial NCT00671593?
This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.